Insight Molecular Diagnostics Inc. IMDX 深 滬
已收盤 05-08 16:00:00 美东时间
5.01
+0.050
+1.01%
華盛通- 最 高5.10
- 今 開4.87
- 成交量 42.22万股
- 最 低 4.55
- 昨 收 4.96
- 總市值 1.62亿
- 52周最高 8.51
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.33
- 委 比 -70.85%
- 總股本 3228.80万
- 歷史最高 204.80
- 量 比 0.59
- 振 幅 11.09%
- 歷史最低 1.922
- 每 手 1
- 風險率 1.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alpha Buying: Insider Conviction in High-Risk Biotech
Insider buying matters in every industry, but it carries a special weight in bi...
05-08 00:04
iMDx to Release First Quarter 2026 Results on May 13, 2026
Insight Molecular Diagnostics Inc. (IMDX) announced it will release its first quarter 2026 financial results after market close on May 13, 2026, followed by a live Zoom webinar at 2:00 pm PT / 5:00 pm ET to discuss the results. Registration for the webinar is available at the provided link, and an archived replay will be accessible on the company’s website post-event. The company aims to improve patient outcomes through innovative molecular diagn...
05-06 20:05
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Apellis Pharmaceuticals (NASDAQ:APLS) shares moved upwards by 138.8% t...
03-31 20:05
Insight Molecular Diagnostics Files GraftAssureDx For Kidney Transplant Rejection Testing For FDA Review
Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results.Submitted GraftAssureDx™ for kidney transplant
03-27 04:16
Insight Molecular Q4 Adj. EPS $(0.27) Misses $(0.24) Estimate, Sales $1.139M Down From $1.486M Last Year
Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.24) by 13.92 percent. This is a 3.57 percent increase over losses of $(0.28) per share
03-27 04:10
Earnings Scheduled For March 26, 2026
Companies Reporting Before The Bell • ProShares UltraShort Russell2000 (NYSE:TW...
03-26 19:11
Insight Molecular Diagnostics Inc. Q4 2025 Earnings Preview
Insight Molecular Diagnostics Inc. (IMDX) is scheduled to announce Q4 earnings results on Thursday, March 26th, after market close. The consensus EPS estimate is -$0.24, and the consensus revenue esti...
03-26 05:35
Insight Molecular Diagnostics publishes financial calendar update
Insight Molecular Diagnostics publishes financial calendar update iMDx will report fourth-quarter financial results after the market closes on March 26, 2026. A live Zoom webinar to discuss the results is scheduled for March 26, 2026 at 2:00 pm PT / 5:00 pm ET, with registration at iMDx Q4 2025 Earn
03-20 20:01
Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score
Insight Molecular Diagnostics Inc. highlighted a new peer-reviewed study demonstrating the potential superiority of its GraftAssure assay technology, featuring 249 biopsy-matched kidney transplant patients. The proprietary Combination Model (CM)-score outperformed percentage-only measures of dd-cfDNA, showing strong correlation with rejection indices, including Antibody-mediated Rejection (AMR) and T-Cell Mediated Rejection (TCMR). The study, con...
03-13 12:00
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Edesa Biotech (NASDAQ:EDSA) shares rose 61.0% to $3.67 during Tuesday'...
03-04 01:05
